Stock · MANKIND · Healthcare
MANKIND share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for MANKIND PHARMA LIMITED, refreshed every end-of-day run. A systematic, data-only read on MANKIND PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads MANKIND as constructive with a Crack Score of 89/100 as of 25 Jul 2026.
BazaarBaaziSource & method
The scanner's readNear-perfect · scanned 24 Jul 2026
Where MANKIND stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
One directional side cleared its price-structure, filed-evidence and signed money-flow gates with no blocking red flag.
Technical axis
100/100Fundamental axis
100/100Money flow
56/100Result pulse · Q4 FY26
100/100Named setups in force
- stage2 uptrend
- pullback to rising MA
- RS leader
- earnings acceleration
- quality margins
- result winner
Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
uptrend frame (50 > 200 DMA)
50DMA rising
pulled back to a rising MA
orderly dip from highs
relative strength rising vs NIFTY
RS line near its highs (leadership)
RS slope +12.9% (3m)
outperforming and above 50DMA
Fundamental evidence
net profit +31.74% YoY
revenue +11.81% YoY
net margin 16.25%
result score 100.0/100
net margin 16.25% (high)
result score 100.0/100
profit not shrinking YoY
revenue +11.81% YoY
result score 100.0/100 (top tier)
strong filed quarter
profit up YoY
revenue up YoY
Valuation and context
P/E 55.2 vs sector median 49.5 (1.12x, 62th pctile)
P/E 1.14x its own ~15m median (48.6)
Relative valuation
P/E (TTM)
55.2P/E vs sector
+1.1%Sector percentile
62PEG
1.74Growth gap
-19.3%P/E vs own history
+1.1%The engine's trade frame
Entry zone
2,557.4Stop
2,457.2Target 1
2,757.8Target 2
2,858.0Risk / reward
3.9% risk · 2.0RScanner levels from the deterministic engine run of 2026-07-24, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 25 Jul 2026
Support and resistance for MANKIND are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the MANKIND chart, refreshed every end-of-day run.
The Crack Score, and how it is built89 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for MANKIND, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on MANKIND reads right now.
The editorial price read on MANKIND is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on MANKIND can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving MANKIND.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why MANKIND moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
MANKIND PHARMA LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
100 / 100Revenue
Rs 3,443 crNet profit
Rs 559 crEPS (quarter)
Rs 13.44| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +11.8% | -3.5% |
| Net profit | +31.7% | +35.2% |
| Net margin | +16.3% | |
Figures are the Q4 FY26 result for MANKIND PHARMA LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter13 quarters on record
MANKIND PHARMA LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 31 Mar 2023. These are quarterly facts, not TTM valuation inputs.
MANKIND official result trail
13 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 3,443 cr | Rs 13.44 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 3,567 cr | Rs 9.90 | n/a | 44/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 3,697 cr | Rs 12.39 | n/a | 56/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 3,570 cr | Rs 10.62 | n/a | 50/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 3,079 cr | Rs 10.19 | n/a | n/a | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 3,230 cr | Rs 9.45 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 3,077 cr | Rs 16.31 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 2,893 cr | Rs 13.39 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 2,441 cr | Rs 11.76 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 2,607 cr | Rs 11.33 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 2,708 cr | Rs 12.51 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 2,579 cr | Rs 12.15 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 2,053 cr | Rs 7.13 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
MANKIND PHARMA LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
14,278 crNet profit (TTM)
1,938 crEBIT (TTM)
2,960 crProfit before tax (TTM)
2,321 crNet margin (TTM)
13.6%Finance costs (TTM)
639 crBalance sheet, as filed 2026-03-31
Total assets
28,080 crShareholder equity
16,561 crTotal borrowings
6,312 crCash and equivalents
392 crInventory
2,144 crTrade receivables
1,730 crThe cash engine, latest filed year
Operating cash flow
3,121 crCapex
737 crFree cash flow
2,384 crInvesting flow
-196 crFinancing flow
-2,953 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 14,278 cr | 1,938 cr | 16,561 cr | 6,312 cr | 3,121 cr |
| FY25 | 12,207 cr | 2,011 cr | 14,568 cr | 8,511 cr | 2,413 cr |
| FY24 | 10,335 cr | 1,942 cr | 9,576 cr | 207 cr | 2,152 cr |
| FY23 | 8,749 cr | 1,310 cr | 7,623 cr | 170 cr | 1,813 cr |
Every figure is parsed from MANKIND PHARMA LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record14 earnings calls
Every MANKIND earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
MANKIND PHARMA LIMITED earnings calls on record
14 calls since 30 Jun 2023
Show 6 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed44 disclosures
Every recent official filing from MANKIND PHARMA LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
MANKIND PHARMA LIMITED has filed 44 official disclosures recently. The most recent is a Investor meet dated 17 Jul 2026.
Event Heat
41 / 100Certificate under SEBI (Depositories and Participants) Regulations, 2018
Event Heat is a dated net read of MANKIND PHARMA LIMITED's last 90 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the MANKIND chart. Not a substitute for a registered research note.
| Ticker | MANKIND |
|---|---|
| Full name | MANKIND PHARMA LIMITED |
| Sector | Healthcare |
| Index class | LARGE CAP |
| ISIN | INE634S01028 |
| Market-cap band | ~1.1 lakh cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | MANKIND |
Reference chartLevels in show
The daily frame the desk reads on MANKIND.
FAQ13 reader questions · AEO-eligible
The line on MANKIND, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the MANKIND share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on MANKIND. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for MANKIND?
The BazaarBaazi Crack Score for MANKIND is 89 out of 100 as of 25 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on MANKIND?
Strike-level option inventory for MANKIND is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is MANKIND in and which peers does BazaarBaazi track?
MANKIND sits in Healthcare (large cap), indicative market cap ~1.1 lakh cr (indicative), ISIN INE634S01028. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on MANKIND PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the MANKIND view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on MANKIND is bullish, published in Systematic Read on 21 Jul 2026.
Is MANKIND a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-24 run of the 500-name BazaarBaazi setup scanner, MANKIND PHARMA LIMITED sits in the Near-perfect tier with a setup score of 89/100 (technical 100, fundamental 100). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read MANKIND PHARMA LIMITED's earnings call transcripts?
BazaarBaazi indexes 14 MANKIND earnings calls going back to 2023-06-30, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was MANKIND PHARMA LIMITED's Q4 FY26 net profit?
MANKIND PHARMA LIMITED reported a net profit of Rs 559 cr for Q4 FY26 (the quarter ended 31 March 2026). That is +31.7% year on year. The figure is from the company's official NSE filing.
What was MANKIND PHARMA LIMITED's Q4 FY26 revenue?
MANKIND PHARMA LIMITED reported revenue of Rs 3,443 cr for Q4 FY26. That is +11.8% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate MANKIND PHARMA LIMITED's Q4 FY26 result?
BazaarBaazi gives MANKIND PHARMA LIMITED's Q4 FY26 result a Result Pulse of 100 out of 100, with a verdict of Profit acceleration. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Mankind Pharma Ltd announced recently?
Mankind Pharma Ltd's two most material recent disclosures are an investor meet dated 17 Jul 2026, "Schedule of meet", and a m&a dated 11 Jul 2026, "Acquisition". Both link to the company's own official filing on the BazaarBaazi stock page.
What did Mankind Pharma Ltd's latest board meeting cover?
Mankind Pharma Ltd's most recent board-meeting disclosure on record dated 11 Jul 2026 reads "Outcome of Board Meeting held on July 11, 2026". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.
Has Mankind Pharma Ltd's credit rating been updated recently?
Mankind Pharma Ltd filed a credit-rating disclosure on 12 May 2026, recorded with the exchange as "Credit Rating". The detail sits in the linked filing on the BazaarBaazi stock page. A rating action is an agency view on debt, separate from the share price.
Related stock views
The names BazaarBaazi reads alongside MANKIND, each a living view refreshed every end-of-day run.